180 related articles for article (PubMed ID: 18824499)
1. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.
Schmidt M; Victor A; Bratzel D; Boehm D; Cotarelo C; Lebrecht A; Siggelkow W; Hengstler JG; Elsässer A; Gehrmann M; Lehr HA; Koelbl H; von Minckwitz G; Harbeck N; Thomssen C
Ann Oncol; 2009 Feb; 20(2):258-64. PubMed ID: 18824499
[TBL] [Abstract][Full Text] [Related]
2. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK
Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588
[TBL] [Abstract][Full Text] [Related]
3. Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.
Blancas I; Gómez FJ; Bermejo B; Hennessy BT; Chirivella I; Magro A; Caballero A; Ferrer J; Valero V; Lluch A
Clin Breast Cancer; 2009 Nov; 9(4):231-6. PubMed ID: 19933078
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
[TBL] [Abstract][Full Text] [Related]
5. Validation and problems of St-Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients.
Iwamoto E; Fukutomi T; Akashi-Tanaka S
Jpn J Clin Oncol; 2001 Jun; 31(6):259-62. PubMed ID: 11463803
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy.
Lin PH; Yeh MH; Liu LC; Chen CJ; Tsui YC; Su CH; Wang HC; Liang JA; Chang HW; Wu HS; Yeh SP; Li LY; Chiu CF
J Surg Oncol; 2013 Nov; 108(6):352-7. PubMed ID: 23996583
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
8. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor.
Saimura M; Fukutomi T; Tsuda H; Sato H; Miyamoto K; Akashi-Tanaka S; Nanasawa T
J Surg Oncol; 1999 Jun; 71(2):101-5. PubMed ID: 10389866
[TBL] [Abstract][Full Text] [Related]
12. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients.
Courdi A; Chamorey E; Ferrero JM; Hannoun-Lévi JM
Radiother Oncol; 2013 Aug; 108(2):259-65. PubMed ID: 23891092
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer.
Heimann R; Ferguson D; Powers C; Recant WM; Weichselbaum RR; Hellman S
J Natl Cancer Inst; 1996 Dec; 88(23):1764-9. PubMed ID: 8944007
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.
Bevilacqua P; Barbareschi M; Verderio P; Boracchi P; Caffo O; Dalla Palma P; Meli S; Weidner N; Gasparini G
Breast Cancer Res Treat; 1995; 36(2):205-17. PubMed ID: 8534868
[TBL] [Abstract][Full Text] [Related]
17. A nomogram to predict individual prognosis in node-negative breast carcinoma.
Mazouni C; Spyratos F; Romain S; Fina F; Bonnier P; Ouafik LH; Martin PM
Eur J Cancer; 2012 Nov; 48(16):2954-61. PubMed ID: 22658808
[TBL] [Abstract][Full Text] [Related]
18. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
[TBL] [Abstract][Full Text] [Related]
19. Application of St Gallen Categories in Predicting Survival for Patients With Breast Cancer in Vietnam.
Nguyen VC; Nguyen TQ; Vu TNH; Phung TH; Nguyen TPH; Nguyen ND; Le DR
Cancer Control; 2019; 26(1):1073274819862794. PubMed ID: 31307207
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
Klintman M; Nilsson F; Bendahl PO; Fernö M; Liljegren G; Emdin S; Malmström P;
Ann Oncol; 2013 Sep; 24(9):2284-91. PubMed ID: 23704202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
